EnGeneIC Doses First Patient with Novel EGFR-Targeted Nanocell Therapy for Recurrent Glioblastoma
核心洞察
EnGeneIC Limited (搜索) has dosed the first patient in a clinical trial evaluating EGFR (搜索)-targeted EDV therapy for recurrent glioblastoma multiforme (搜索), an aggressive and currently incurable brain cancer (搜索).
The investigational treatment uses bacterially derived nanocell particles loaded with doxorubicin and α-galactosyl ceramide (搜索) to target EGFR (搜索)-overexpressing tumor cells while activating immune responses.
The trial builds on promising survival outcomes from compassionate use cases and aims to address the significant unmet need in recurrent GBM patients who have exhausted standard treatment options.
EnGeneIC Limited (搜索) has achieved a significant milestone by dosing the first patient in its clinical trial evaluating an investigational EGFR (搜索)-targeted nanocell therapy for patients with recurrent glioblastoma multiforme (搜索) (GBM), marking a potential breakthrough for one of the most challenging cancers to treat.
The trial is being conducted at Westmead Hospital (搜索), one of Australia's leading comprehensive cancer centres, under the leadership of Principal Investigator Dr. Mark Wong, Medical Oncologist. Additional recruitment sites include the Kinghorn Cancer Centre (搜索) in Australia, with planned expansion to clinical sites in Singapore.
Novel Dual-Payload Nanocell Technology
The investigational treatment consists of EGFR (搜索)-targeted EnGeneIC Dream Vectors (EDVs) — bacterially derived, nanocell-based particles engineered to selectively bind to epidermal growth factor receptor (搜索) (EGFR), which is frequently over-expressed in glioblastoma. The EDVs are loaded with the chemotherapeutic agent doxorubicin and the immune-modulating adjuvant α-galactosyl ceramide (搜索) (α-GalCer).
This dual-payload design is intended to directly kill EGFR (搜索)-expressing tumour cells while simultaneously activating a broad anti-tumour immune response, potentially converting an immunologically "cold" tumour into one capable of sustained immune recognition and attack.
Addressing Critical Unmet Medical Need
"This first patient dosed milestone is a critical step forward for patients with recurrent glioblastoma, who typically have very limited treatment options once standard therapies have failed," said Dr. Mark Wong. "We look forward to assessing the safety and potential clinical benefit of this investigational therapy in a patient population with significant unmet medical need."
Recurrent GBM remains highly resistant to conventional chemotherapy and immunotherapy, and EGFR (搜索)-targeted EDVs offer a novel approach by combining targeted intracellular drug delivery with immune activation in a disease where both effective tumour penetration and immune engagement have historically been major challenges.
Promising Compassionate Use Data
Dr. Jennifer MacDiarmid, Joint CEO and Director of EnGeneIC, highlighted the clinical rationale supporting the trial advancement: "This clinical trial builds on spectacular overall survival outcomes currently observed in Compassionate Case Study patients with recurrent glioblastoma who had exhausted all available treatment options. Those results provided the strong clinical rationale to advance this EGFR (搜索)-targeted EDV therapy into a formal clinical trial, allowing us to rigorously evaluate both its anti-cancer and immune-stimulating potential."
Disease Background and Treatment Landscape
Glioblastoma multiforme (搜索) is the most common and aggressive primary brain cancer (搜索) in adults. Despite treatment with surgery, radiation and chemotherapy, recurrence is common and survival outcomes remain poor, highlighting the urgent need for new therapeutic approaches.
Patient recruitment is expected to continue across Australian and Singaporean sites in accordance with the trial protocol and applicable regulatory approvals. EnGeneIC's proprietary EDV technology platform is designed to deliver therapeutic payloads directly to cancer cells while simultaneously engaging the immune system to support durable anti-tumour responses, with minimal to no toxic side effects.